Trials / Completed
CompletedNCT06031194
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.
Detailed description
PRIMARY OBJECTIVES: I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity. OUTLINE: This is an observational study. Participants undergo blood sample collection and have their medical records reviewed on study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional Study | Non-interventional study |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2025-11-05
- Completion
- 2025-12-23
- First posted
- 2023-09-11
- Last updated
- 2026-01-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06031194. Inclusion in this directory is not an endorsement.